Scientists have successfully used three combination therapies to treat thyroid cancer!

December 21, 2020 // -- A recent article published in the international magazine Journal for ImmunoTherapy of Cancer entitled "Combining BRAF resedion with oncolytic herpes simplex virus enhances the immune-mediated anti Scientists from institutions such as the London Cancer Institute have found that combining a gene-targeted drug, a cancer outbreak virus and a drug that removes the immune system's brake pedals could hopefully help fight thyroid cancer, according to a study by BRAF-mutant thyroid cancer.
the triple therapy may attack cancer's ability to withstand a single drug in a multi-pronged manner, researchers have now achieved significant therapeutic results in mice.
, the researchers analyzed thyroid cancer that expresses the mutated gene BRAF, which drives the growth of cancer in tumors.
researchers have developed a BRAF inhibitor that targets mutations in the gene that act, and has shown significant results in the treatment of thyroid cancer and melanoma, both of which carry the mutation.
in many cases, however, cancer quickly resists the effects of the drug, which gradually weakens over time, giving cancer cells the upper hand again.
Photo Source: NIH, CC BY-NC 2.0 In this study, researchers tried to combine three treatment models to target genetic defects while stimulating the host body's immune system to fight tumors.
The BRAF drug, called PLX4720, worked well in the first place, followed by a genetically engineered herpes virus and an antibody called checkpoint inhibitor, and when combined, the mice survived longer and had smaller tumor sizes in their bodies, which extended the survival time of the combined therapy by 66 percent compared to the control group.
T-VEC virus, similar to the virus used in this article, has been approved for clinical use.
T-VEC as a viral immunotherapy that targets tumor cells by modifying the herpes simplex virus.
is currently only approved for use in patients with advanced melanoma, but also in clinical trials of other cancers, i.e. as a monotherapy or in combination with other immunotherapies.
Although these viruses can have a direct targeted killing effect on cancer cells, what makes the lysovirus even more useful is its ability to trick the host body's immune system into taking local action by sending signals to critical immune cells (T cells) to deal with tumors.
are currently conducting phase I, II and III clinical trials of T-VEC.
The combination therapy may be the way scientists hope to help overcome cancer drug tolerance, and it is the focus of a daily study by researchers who aim to develop a new generation of drugs to change the lives of millions of cancer patients.
researcher Professor Alan Melcher explained: 'We have the most promising results in this study, which suggest that when combined therapy is used to treat thyroid patients, it may have magical therapeutic effects.'
the results of this paper provide a solid basis for scientists to further clarify the role of T-cells at a later stage and how they play a role in cancer.
hope to combine these therapies in future clinical trials to help develop new therapies that could truly change patient treatment.
considering that this particular genetic defect may be associated with two types of cancer, the results of this paper can help improve understanding of the pathogenesis of thyroid cancer, in addition to changing the understanding of the pathogenesis of melanoma.
(Bio on.com) References: Eva Crespo-Rodriguez, Katharina Bergerhoff, Galabina Bozhanova, et al. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer, Journal for ImmunoTherapy of Cancer (2020). DOI:10.1136/jitc-2020-000698【2】Researchers target thyroid cancer with triple threat drug combinationby Institute of Cancer Research。